One of the things that makes CCR5 such a good target for treatment is that there is a much larger quantity of it then other receptors and blockade will have better effect. However there may be genetic mutations that heavily upregulate expression of other receptors which could give them a competitive advantage against CCR5. That could lead to non-responsiveness to treatment by leronlimab.